BLCO Logo

Bausch + Lomb Corporation (BLCO) Insider Trading Activity

NYSE$11.55
Market Cap
$4.08B
Sector
Healthcare
Industry
Medical—Instruments & Supplies
Rank in Sector
177 of 877
Rank in Industry
11 of 46

BLCO Insider Trading Activity

BLCO Median Price and Trade Amounts History Chart

Statistics of Insider Transactions

Amount of Insider Buys and Sells

Buys
$524,992
2
100
Sells
$0
0
0

Related Transactions

SAUNDERS BRENT LCEO and Chairman of the Board
1
$505,067
0
$0
$505,067
VON ESCHENBACH ANDREW C.director
1
$19,925
0
$0
$19,925

About Bausch + Lomb Corporation

Bausch + Lomb Corporation operates as an eye health company worldwide. It operates through three segments: Vision Care/Consumer Health Care, Ophthalmic Pharmaceuticals, and Surgical. The Vision Care/Consumer Health Care segment provides contact lens that covers the spectrum of wearing modalities, including daily disposable and frequently replaced contact lenses; and contact lens care products, over-the-counter eye drops, eye vitamins, and mineral supplements that address various conditions comprising eye allergies, conjunctivitis, and dry eye. The Ophthalmic Pharmaceuticals segment offers proprietary and generic pharmaceutical products for post-operative treatments, as well as for the treatment of eye conditions, such as glaucoma, ocular hypertension, and retinal diseases; and contact lenses for therapeutic use. The Surgical segment provides tools and technologies for the treatment of cataracts, and vitreous and retinal eye conditions; and intraocular lenses and delivery systems, phacoemulsification equipment, and other surgical instruments and devices. The company was founded in 1853 and is headquartered in Vaughan, Canada.

Insider Activity of Bausch + Lomb Corporation

Over the last 12 months, insiders at Bausch + Lomb Corporation have bought $524,992 and sold $0 worth of Bausch + Lomb Corporation stock.

On average, over the past 5 years, insiders at Bausch + Lomb Corporation have bought $524,992 and sold $674.53M worth of stock each year.

Highest buying activity among insiders over the last 12 months: SAUNDERS BRENT L (CEO and Chairman of the Board) — $505,067. VON ESCHENBACH ANDREW C. (director) — $19,925.

The last purchase of 1,695 shares for transaction amount of $19,925 was made by VON ESCHENBACH ANDREW C. (director) on 2025‑05‑02.

List of Insider Buy and Sell Transactions, Bausch + Lomb Corporation

2025-05-02PurchaseVON ESCHENBACH ANDREW C.director
1,695
0.0005%
$11.76
$19,925
-1.04%
2024-08-05PurchaseSAUNDERS BRENT LCEO and Chairman of the Board
32,250
0.0093%
$15.66
$505,067
+10.13%
2022-06-01SaleBausch Health Companies Inc.
9.1M
2.724%
$17.05
$155.21M
-1.47%
2022-05-10SaleBausch Health Companies Inc.
70M
19.4359%
$17.05
$1.19B
-8.60%
Total: 4
*Gray background shows transactions not older than one year

BLCO Institutional Investors: Active Positions

Increased Positions61+42.66%9M+22.94%
Decreased Positions63-44.06%7M-19.49%
New Positions30New6MNew
Sold Out Positions29Sold Out3MSold Out
Total Postitions141-1.4%39M+3.46%

BLCO Ownership Change vs Market

Institutional Investor Ownership

Top Shareholders
Top Buyers
Top Sellers
New Shareholders
Sold-Out Shareholders
Active Shareholders
Icahn Carl C$40,250.000.99%3.5M00%2024-12-31
Maple Rock Capital Partners Inc.$36,467.000.9%3.17M-446,495-12.34%2024-12-31
Alberta Investment Management Corp$34,594.000.85%3.01M+796,400+36.01%2024-12-31
D. E. Shaw & Co., Inc.$21,672.000.53%1.88M-29,750-1.55%2024-12-31
Goldentree Asset Management Lp$19,920.000.49%1.73M-2M-48.38%2024-12-31
River Road Asset Management, Llc$17,330.000.43%1.51M-513,428-25.41%2024-12-31
Whitebox Advisors Llc$16,596.000.41%1.44M+199,856+16.07%2024-12-31
Nomura Holdings Inc$14,446.000.36%1.26M00%2024-12-31
Arrowstreet Capital, Limited Partnership$14,012.000.35%1.22M+414,138+51.49%2024-12-31
King Street Capital Management, L.P.$13,068.000.32%1.14M+404,256+55.22%2024-12-31

Financial Ratios

Summary
Comparison with Competitors

Price to Earnings

Price/Earnings to Growth

Price to Sales

Price to Book

Price/Free Cash Flow

Analyst Recommendations

Analyst Price Targets

Prismo does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. Prismo does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.